| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
100,490,000 |
| Market
Cap: |
7.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.24 - $94.5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. Co.'s primary clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRss). Co. is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRss for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
348,181 |
852,260 |
908,260 |
1,615,026 |
| Total Sell Value |
$27,122,482 |
$40,299,016 |
$41,683,016 |
$54,614,939 |
| Total People Sold |
2 |
4 |
6 |
6 |
| Total Sell Transactions |
2 |
9 |
11 |
23 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Masamune Hiroko |
Chief Development Officer |
• – – |
2019-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
22,667 |
141,063 |
|
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2018-09-25 |
4 |
S |
$19.15 |
$5,034,250 |
D/D |
(262,881) |
6,038,083 |
|
- |
|
| Masamune Hiroko |
Chief Development Officer |
• – – |
2018-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
111,197 |
|
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2018-05-31 |
4 |
S |
$9.25 |
$199,347 |
D/D |
(21,551) |
94,035 |
|
- |
|
| Singleton J Matthew |
Director |
– • – |
2018-05-31 |
4 |
B |
$9.82 |
$93,261 |
D/D |
9,500 |
9,500 |
2.39 |
- |
|
| Rowland Charles A Jr |
Director |
– • – |
2018-05-29 |
4 |
B |
$5.16 |
$154,800 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
| Webster Stephen W |
Director |
– • – |
2018-05-29 |
4 |
B |
$5.21 |
$41,712 |
D/D |
8,000 |
8,000 |
2.39 |
- |
|
| Macartney Lawson |
Director |
– • – |
2018-05-29 |
4 |
B |
$5.22 |
$250,329 |
D/D |
47,965 |
47,965 |
2.39 |
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2018-05-04 |
4 |
D |
$4.22 |
$32,140 |
D/D |
(7,616) |
94,035 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2018-05-04 |
4 |
D |
$4.22 |
$42,563 |
D/D |
(10,086) |
1,483,012 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2018-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
1,493,098 |
|
- |
|
| Morneau Michael |
Chief Financial Officer |
• – – |
2018-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
101,651 |
|
- |
|
| Morneau Michael |
Chief Financial Officer |
• – – |
2017-05-04 |
4 |
D |
$1.34 |
$10,977 |
D/D |
(8,192) |
80,604 |
|
- |
|
| Foehr Matthew W |
Director |
– • – |
2016-11-15 |
4 |
B |
$1.21 |
$15,678 |
D/D |
13,000 |
39,250 |
2.39 |
- |
|
| Hanley Rochelle |
Chief Medical Officer |
• – – |
2016-05-04 |
4 |
D |
$1.31 |
$13,879 |
D/D |
(10,595) |
160,836 |
|
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2016-04-13 |
4 |
OE |
$1.25 |
$1,200,000 |
D/D |
960,000 |
6,300,964 |
|
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2016-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
560,000 |
5,340,964 |
|
- |
|
| Foehr Matthew W |
Director |
– • – |
2016-04-13 |
4 |
B |
$1.24 |
$24,800 |
D/D |
20,000 |
26,250 |
2.39 |
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2015-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
228,105 |
4,780,964 |
|
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2015-05-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,552,859 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2015-05-04 |
4 |
A |
$9.49 |
$155,124 |
D/D |
16,346 |
1,453,098 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2015-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,658 |
1,436,752 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2015-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
87,500 |
1,424,094 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2015-05-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,313,406) |
1,336,594 |
|
- |
|
| Dinerman Michael |
Chief Operating Officer |
• – – |
2015-05-04 |
4 |
A |
$9.49 |
$82,791 |
D/D |
8,724 |
694,116 |
|
- |
|
162 Records found
|
|
Page 6 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
6.56 (8.18%) 
